Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study

Summary

This is a phase three study to evaluate the safety and efficacy of Pradefovir treatment in chronic hepatitis B patients. Subject will be randomized to Pradefovir group and TDF group at a ratio of 2:1. Treatment duration will be 96w in randomization and followed by 48w in open. The interim analysis will be conducted when all subject completed the first 48-week treatment.

Timeline

Start

2020-09

Primary completion

2022-10

Completion

2024-12

Drugs

Indications